Tag: nature

8.3

DUBLIN, Ireland, July 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fusion Fuel Green PLC (NASDAQ: HTOO) (“Fusion Fuel” or the “Company”), a provider of integrated energy solutions, today announced that Bright Hydrogen Solutions Ltd (“BrightHy Solutions”), a Fusion Fuel subsidiary and provider of hydrogen solutions, executed a non-binding Term Sheet (the “Term Sheet”) outlining the terms of a strategic partnership focused on investments in hydrogen projects and infrastructure with an integrated green energy technologies provider (the “Partner”). As contemplated by the Term Sheet, subject to execution of one or more binding agreements, the Partner would commit up to €30 million in capital over four years to be invested in certain hydrogen projects. These investments are expected to be channeled through special purpose vehicles held by a newly created investment entity to be majority-owned by the Partner.

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that its board of directors has declared a monthly ordinary dividend of $0.2575 per share of common stock, which is the equivalent of an annualized dividend of $3.09 per share. The dividend is payable in cash on August 15, 2025 to shareholders of record at the close of business on July 31, 2025.

CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.